The acquisition significantly strengthens Abbott's position in high-growth cancer diagnostics. Traders should monitor integration progress and synergy realization. The deal may lead to upward revisions in Abbott's long-term growth guidance.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 23 $104.84entry
- T+1 · 8mo ago −0.76%α −0.41% · $104.04
- T+5 · 8mo ago −2.84%α +0.72% · $101.86
- T+20 · 7mo ago −11.55%α −18.97% · $92.73
- T+60 · 5mo ago −13.56%α −28.05% · $90.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abbott Laboratories completed the acquisition of Exact Sciences for $105.00 per share in cash, establishing Abbott as a leader in cancer screening and diagnostics. The deal adds Exact Sciences' portfolio, including Cologuard and Oncotype DX, to Abbott's diagnostics business.
Key Facts
- Abbott completed the acquisition of Exact Sciences on March 23, 2026
- Exact Sciences shareholders received $105.00 per share in cash
- Exact Sciences is now a wholly owned subsidiary of Abbott
- The deal establishes Abbott as a leader in the $60 billion U.S. cancer screening and precision oncology diagnostics market
- Key products acquired include Cologuard, Oncotype DX, Oncodetect, and Cancerguard
Financial Impact
Total deal value approximately $13.7 billion based on Exact Sciences' ~130 million shares outstanding at $105/share
Risk Factors
- Integration challenges between the two organizations
- Failure to realize anticipated synergies
- Regulatory or operational hurdles in combining the businesses
- Potential dilution of Abbott's earnings in the near term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-033079 |
| Document: tm268709d2_ex99-1.htm | 0001104659-26-033079 |
| Document: 0001104659-26-033079-index-headers.html | 0001104659-26-033079 |
| Document: 0001104659-26-033079-index.html | 0001104659-26-033079 |
| Document: 0001104659-26-033079.txt | 0001104659-26-033079 |
Track record
38 reports on ABT
7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $108.52 −1.28% settles Dec 7
- Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $108.52 +5.26% settles Nov 24
- Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $108.52 +5.73% settles Nov 25
- Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $108.52 +5.86% settles Nov 19
- Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
- Oct 21, 202626d ago 8-K Bearish 6/10 No price data
- Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
- Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
- Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $108.52 +4.29% ▲ +3.26% +6.72% vs SPY
- Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $108.52 +3.46% ▲ +3.46% +4.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers